Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
Follow-Up Questions
Who is the CEO of Bright Minds Biosciences Inc?
Mr. Ian Mcdonald is the President of Bright Minds Biosciences Inc, joining the firm since 2019.
What is the price performance of DRUG stock?
The current price of DRUG is $50.14, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Bright Minds Biosciences Inc?
Bright Minds Biosciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Bright Minds Biosciences Inc market cap?
Bright Minds Biosciences Inc's current market cap is $355.0M
Is Bright Minds Biosciences Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Bright Minds Biosciences Inc, including 3 strong buy, 3 buy, 1 hold, 0 sell, and 3 strong sell
